What is the Role of High-dose Chemotherapy and Autologous Marrow Support for Patients with Breast Cancer?

Bezwoda W.R. , Seymour L. , Dansey R.D. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995; 13: 2483–2489.

Antman K. , Corringham R. , de Vries E. Dose intensive therapy in breast cancer. Bone Marrow Transplant. 1992; 10(suppl 1): 67–73.

Antman K. , Rowlings P.A. , Vaughan W.P. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997. In press.

Rowlings P.A. , Antman K.A. , Horowitz M.M. Prognostic factors in autotransplants for metastatic breast cancer. Blood. 1995; 86(suppl 1): A2459.

Hortobagyi G.N. , Piccart-Gebhart M.J. Current management of advanced breast cancer. Semin Oncol. 1996; 23(suppl 11): 1–5.

Vaughan W.P. , Reed E.C. , Edward B. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant. 1994; 13: 619–624.

Williams S. , Mick R. , Dresser R. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol. 1992; 10: 1743–1747.

Antman K. , Ayash L. , Elias A. A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992; 10: 102–110.

Williams S.F. , Zimmerman T. , Grad G. Source of stem cells rescue: bone marrow versus peripheral-blood progenitors. J Hematother. 1993; 2: 521–523.

Rowe J.M. , Ciobanu N. , Ascensao J. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation: a report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med. 1994; 120: 143–158.

Kessinger A. Reestablishing hematopoiesis after dose-intensive therapy with peripheral stem cells. In: Armitage J.O. , Antman K.H. , eds. High-dose Cancer Chemotherapy: Pharmacology, Hematopoietins, Stem Cells. 2nd ed. Baltimore, Md: Williams & Wilkins; 1995: 196–210.

Geils G.J. Jr , Tilden A.B. , Briggs A.D. A strategy for successful single large-volume leukopheresis (LVL) of patients following G-CSF-only mobilization: results of 45 patients. Proc Annu Meet Am Soc Clin Oncol. 1996; 15: A341.

Vahdat L. , Antman K. High-dose therapy for breast cancer. Blood Rev. 1995; 9: 191–200.

Bonadonna G. , Valagussa P. , Moliterni A. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995; 322: 901–906.

Crump M. , Goss P.E. , Prince M. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol. 1996; 14: 66–69.

Hryniuk W. , Levine M.N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986; 4: 1162–1170.

Tannock I.F. , Boyd N.F. , DeBoer G. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988; 6: 1377–1387.

Dimitrov N. , Anderson S. , Fisher B. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: findings from NSABP-22. Proc Annu Meet Am Soc Clin Oncol. 1994; 13: A64.

Lazarus H.M. , Reed M.D. , Spitzer T.R. High-dose IV thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep. 1987; 71: 689–695.

Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992; 339: 1–15, 71–85.

Schumacher M. , Bastert G. , Bojar H. Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Clin Oncol. 1994; 12: 2086.

Rahman Z. , Kavanagh J. , Giles R. Paclitaxel immediately following autologous bone marrow transplantation further reduces residual disease in patients with metastatic breast cancer. Proc Am Assoc Cancer Res. 1997; 38: 25. Abstract.